Skip to main
PRTA

Prothena (PRTA) Stock Forecast & Price Target

Prothena (PRTA) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Prothena Corp showcases a promising future driven by a robust clinical pipeline of investigational therapeutics targeting various neurodegenerative and rare diseases, particularly with its programs like NEOD001 for amyloidosis and PRX002 for Parkinson's disease. The company has guided that it could potentially earn up to $105 million in aggregate milestones by 2026, translating to approximately $2 per basic share outstanding, through partnerships with major pharmaceutical companies such as Novo Nordisk and Bristol-Myers Squibb. Additionally, despite some concerns regarding elevated ARIA incidence in PRX012-treated patients, the overall data indicates a favorable reduction in amyloid levels, alongside the therapy being well-tolerated with low incidence of injection-site reactions.

Bears say

Prothena Corp PLC faces a negative outlook primarily due to its ongoing net losses, which are expected to persist until product approval and likely through the initial commercialization phase. The company is anticipated to require additional capital in the short term to continue developing its drug candidates, raising concerns about potential dilution of shareholder value. Moreover, regulatory and clinical risks present uncertainties that could further complicate the approval processes for its investigational therapeutics, adding to the financial challenges ahead.

Prothena (PRTA) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prothena (PRTA) Forecast

Analysts have given Prothena (PRTA) a Buy based on their latest research and market trends.

According to 9 analysts, Prothena (PRTA) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prothena (PRTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.